Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

86.7%

+0.2% vs industry average

Late-Stage Pipeline

18%

3 trials in Phase 3/4

Results Transparency

0 of 13 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

9(52.9%)

Phase 3

3(17.6%)

Phase 1

3(17.6%)

N/A

2(11.8%)

17Total

Phase 2(9)

Phase 3(3)

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT05363397Phase 2Recruiting

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

Role: collaborator

NCT03234686Phase 2Completed

Deferiprone to Delay Dementia (The 3D Study)

Role: lead

NCT03385928Phase 2Completed

STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Role: lead

NCT04776031Not ApplicableCompleted

Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes

Role: collaborator

NCT02899611Phase 1Completed

A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures

Role: collaborator

NCT04759365Phase 1Terminated

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

Role: collaborator

NCT05070702Phase 1Completed

First in Human Study of CT-1500 in Healthy Participants

Role: collaborator

NCT03494920Phase 3Completed

DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval

Role: lead

NCT03287076Phase 2Unknown

Trial of EXenatide in Acute Ischaemic Stroke

Role: lead

NCT03340493Phase 2Completed

Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

Role: lead

NCT01702636Phase 2Completed

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

Role: lead

NCT02868580Phase 2Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

Role: lead

NCT01580839Phase 3Completed

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

Role: lead

NCT00887328Phase 3Completed

Extending the Time for Thrombolysis in Emergency Neurological Deficits

Role: lead

NCT02388061Phase 2Completed

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

Role: lead

NCT01492725Phase 2Terminated

Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial

Role: lead

NCT01846247Not ApplicableCompleted

A Very Early Rehabilitation Trial

Role: lead

All 17 trials loaded